Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6M
1M shares
52-week range
$1.42 – $29.00
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
53.39%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.0M | $1.0M | $0 | $0 | $195.8K | $0 | $0 |
| Cost of revenue | $0 | $80 | $58 | $55 | $120 | $196.0K | $186.0K | $0 |
| Gross profit | $1.0M | $999.9K | $999.9K | −$55 | −$120 | −$196 | −$186.0K | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | -0.1% | — | — |
| R&D | $5.3M | $2.3M | $7.5M | $11.8M | $16.3M | $17.0M | $7.6M | $3.7M |
| Operating income | −$7.8M | −$7.2M | −$13.2M | −$17.9M | −$22.6M | −$22.3M | −$11.0M | −$27.5M |
| EBITDA | −$5.6M | −$6.1M | −$28.4M | −$17.5M | −$21.5M | −$19.9M | −$7.1M | −$26.3M |
| Net income | −$5.2M | −$5.8M | −$28.0M | −$18.4M | −$21.7M | −$19.9K | −$7.2M | −$26.4M |
| Net margin | -520.0% | -585.0% | -2799.9% | — | — | -10.2% | — | — |
| EPS (diluted) | -740.00 | -560.00 | -500.00 | -200.00 | -240.00 | -180.00 | -44.20 | -11080.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-5.31 | $-5.31–$-5.31 | 1 |
| 2027 | $36M | $-0.88 | $-0.88–$-0.88 | 1 |
| 2028 | $7M | $-0.15 | $-0.15–$-0.15 | 1 |
| 2029 | $33M | $0.07 | $0.07–$0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
www.purple-biotech.comNo one on the platform currently holds PPBT.
No tracked institution reports a position in PPBT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-03-02 | 1-for-10reverse |
| 2024-09-17 | 1-for-20reverse |
| 2020-08-21 | 1-for-10reverse |
No one on the platform has traded PPBT yet.
| $2999 |
| — |
| MSPRMSP Recovery, Inc. | $0.02 | -20.31% | $210748 | — |
| PBMPsyence Biomedical Ltd. | $3.12 | +0.65% | $59339 | — |
Source: Financial Modeling Prep · peers by sector/industry
$PPBT lost 50k here and know of at least 50-75 others that lost their ass on this over the last 3-4 years. Took me almost 2.5 years to get close to green all time. This is where money goes to die
View on StockTwits ↗$PPBT put it this way, retail was scammed, lied to, and used as an ATM for management to keep the lights on and their insane salaries continuing. And the pumpers in this stock helped them!
View on StockTwits ↗$PPBT .. Yes, it looks like we have some muddy waters to go through… 👇
View on StockTwits ↗$PPBT Because of the company’s distressed financial situation any deal is not going to be ”HUGE” Here is a realistic assumption for a license-deal for each assets…. And bear in mind that NT219 have to pay back around $10M to Yissum, Birad and the israel state if it’s taken out of Israel. Yes, there’s also some other payment’s for CM24 that have to be reimbursed to TMH.
View on StockTwits ↗$PPBT Shareholders vote here will have no impact on anything if management needs approval! Purple Biotech Ltd. is authorized to issue up to 50,000,000 non-voting senior preferred shares without shareholder approval. - And the board has the authority to set the conversion terms at the exact time of issuance.
View on StockTwits ↗$PPBT Current Status: As of late June 2026, the lawsuit remains ongoing and unresolved. Purple Biotech continues to formally reject all allegations made by the Atzmon Plaintiffs.
View on StockTwits ↗$PPBT Only 39 days left….. 👍 D. Property, Plant and Equipment All of our facilities are leased, and we do not own any real property. The principal executive offices for Purple Biotech, TyrNovo, FameWave and Immunorizon are in a commercial office building located in the Science Park in Rehovot, Israel. On July 27, 2025, we signed an amendment to our existing lease agreement for this office The agreement extends the lease term by 12 months, running from January 1, 2026, through December 31, 2026. Additionally, we were granted an option to extend the lease for another 48 months, potentially continuing the term until December 31, 2030. This option renews automatically unless we provide written notice of our intent not to renew at least 150 days before the end of the 2026 extension. We have no material tangible fixed assets apart from the property described above. We believe our facilities are adequate and suitable for our current needs.
View on StockTwits ↗$PPBT Buying more buyout lottery tickets. Best to have no concrete expectations on a timeline though.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.